Sigilon Therapeutics, Inc. (SGTX)

NASDAQ: SGTX · IEX Real-Time Price · USD
0.750
+0.011 (1.49%)
Aug 11, 2022 4:30 PM EDT - Market closed
1.49%
Market Cap 24.28M
Revenue (ttm) 9.99M
Net Income (ttm) -66.11M
Shares Out 32.40M
EPS (ttm) -2.25
PE Ratio n/a
Forward PE 2.77
Dividend n/a
Ex-Dividend Date n/a
Volume 14,713
Open 0.716
Previous Close 0.739
Day's Range 0.729 - 0.770
52-Week Range 0.680 - 6.910
Beta n/a
Analysts Buy
Price Target 4.03 (+437.7%)
Earnings Date Aug 8, 2022

About SGTX

Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progressio... [Read more...]

Industry Biotechnology
IPO Date Dec 4, 2020
Employees 66
Stock Exchange NASDAQ
Ticker Symbol SGTX
Full Company Profile

Financial Performance

In 2021, SGTX's revenue was $9.60 million, a decrease of -28.23% compared to the previous year's $13.37 million. Losses were -$77.31 million, 41.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for SGTX stock is "Buy." The 12-month stock price forecast is 4.03, which is an increase of 437.69% from the latest price.

Price Target
$4.03
(437.69% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Sigilon Therapeutics, Inc. (SGTX) Reports Q2 Loss, Tops Revenue Estimates

Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of 4.35% and 22.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sigilon Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

Company expects to report results of preclinical MPS-1 studies in second half of 2022 to inform pipeline strategy Company expects to report results of preclinical MPS-1 studies in second half of 2022 to...

Sigilon Therapeutics, Inc. (SGTX) Reports Q1 Loss, Tops Revenue Estimates

Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of -43.33% and 27.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Sigilon Therapeutics Reports First Quarter 2022 Financial Results And Business Highlights

On track to announce results from preclinical studies of SIG-005 in second half of 2022

Sigilon Therapeutics to Present at the Needham Healthcare Conference

CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded L...

Sigilon Therapeutics, Inc. (SGTX) Reports Q4 Loss, Misses Revenue Estimates

Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of -19.57% and 47.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the ...

Sigilon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

Announced strategic reprioritization, with plans to advance mucopolysaccharidosis type I (MPS-1) and diabetes as lead indications as well as continued platform optimization

Sigilon Therapeutics to Present at the Barclays Global Healthcare Conference

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded L...

4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry

Some business disruption due to COVID-19 was felt by the Medical-Drugs industry players in 2021. CPRX, KDNY, ASRT and SGTX may prove to be good additions to one's portfolio.

Other symbols: ASRTCPRXKDNY

Sigilon Therapeutics Appoints Sarah Yuan, Ph.D., as Chief Technical Operations Officer

CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li...

Bears are Losing Control Over Sigilon Therapeutics, Inc. (SGTX), Here's Why It's a 'Buy' Now

Sigilon Therapeutics, Inc. (SGTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions...

Sigilon Therapeutics to Present Preclinical Data at the 18th Annual WORLDSymposium™ on Lysosomal Diseases, MPS-1 and ...

CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li...

Sigilon Therapeutics Announces Strategic Reprioritization

- Company plans to prioritize MPS-1 and diabetes with continued focus on platform optimization –

Sigilon Therapeutics Issues An Update On Its Early-Stage Hemophilia Study

Sigilon Therapeutics Inc (NASDAQ: SGTX) reported that fibrosed spheres were observed during a retrieval procedure in a patient in its Phase 1/2 study of SIG-001 in severe or moderately severe hemophilia...

Sigilon Therapeutics Announces Update on SIG-001 Phase 1/2 Study in Hemophilia A

CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Liv...

Sigilon Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

Company expects to complete its investigation of the clinical hold on its Phase 1/2 trial of SIG-001

Sigilon Therapeutics to Participate in the Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Liv...

Sigilon Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights

CAMBRIDGE, Ma., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Livin...

Sigilon Therapeutics Presents Preclinical Data at the 16th International Symposium on MPS and Related Diseases

Company selected for oral presentation on mucopolysaccharidosis-1 (MPS-1), demonstrating potential of SIG-005 to provide sustained production of active human alpha-L-iduronidase in a preclinical model C...

Sigilon Therapeutics Appoints Ajay Rai, M.B.A., as Senior Vice President, Head of Business Development

CAMBRIDGE, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Liv...

Sigilon (SGTX) Down as FDA Places Hold on Hemophilia Study

Sigilon (SGTX) stock declines as the FDA puts a clinical hold on its early/mid-stage hemophilia A study that was evaluating its lead candidate SIG-001.

Here's Why Sigilon Therapeutics Stock Is Tanking Today

A clinical hold for the company's lead candidate wasn't what investors wanted to hear this morning.

Why Galectin Is Soaring And Sigilon Is Sinking Today

Galectin Therapeutics Inc. (NASDAQ: GALT) and Sigilon Therapeutics, Inc. (NASDAQ: SGTX) are among the biggest movers among biopharma stocks in early trading Friday. Galectin Spikes On Positive Data For ...

Other symbols: GALT

Serious Adverse Event Triggers FDA Clinical Hold On Sigilon Therapeutics' Hemophilia A Trial, Shares Drop

The FDA has instituted a clinical hold on Sigilon Therapeutics Inc's (NASDAQ: SGTX) Phase 1/2 study of SIG-001 in patients with severe or moderately severe hemophilia A.  The clinical hold was initiated...

Sigilon Therapeutics Announces Clinical Hold on SIG-001 Phase 1/2 Study in Hemophilia A

CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Liv...